等待开盘 04-02 09:30:00 美东时间
-0.070
-3.40%
Creative Medical Technology Holdings Inc. (CELZ) has achieved its second INN milestone with the WHO, with "etaroleucel" proposed for CELZ-101, its autologous Treg immunotherapy program. This builds on the prior INN approval of "olastrocel" for CELZ-201, highlighting the company's ability to advance multiple cell therapy programs. The milestones underscore regulatory progress and global credibility, supporting future clinical development and comme...
02-10 14:00
Gainers INVO Fertility (NASDAQ:IVF) shares increased by 345.6% to $3.62 during...
01-20 20:05
Creative Medical Technology Holdings shares are trading higher after the compan...
01-06 22:18
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) announced regulatory approval for its BioDefense Inc. Burn Pit Initiative, a program aimed at addressing long-term health consequences for U.S. military veterans exposed to toxic burn pits. The initiative leverages AI and induced pluripotent stem cell (iPSC) technology to build a comprehensive database and develop regenerative solutions. No additional fundraising is required, as the progra...
01-06 14:15
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced the successful completion of patient enrollment in its
2025-12-17 22:16
Creative Medical Technology Holdings, Inc. (CELZ) successfully completed patient enrollment in its FDA-cleared ADAPT clinical trial for CELZ-201, a cell therapy targeting chronic lower back pain. The trial met a critical milestone after an independent safety review confirmed CELZ-201's favorable safety profile. With enrollment complete, CELZ is now progressing to data analysis and后期 follow-up. CELZ-201, an "off-the-shelf" allogenic cell therapy, ...
2025-12-17 14:15
Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company developing next-generation regenerative and immune cell therapies, today announced
2025-12-02 22:19
Creative Medical Technology Holdings, Inc. announced that the World Health Organization (WHO) has approved "olastrocel" as the International Non-Proprietary Name (INN) for CELZ-201, the company's lead allogeneic cell therapy. This milestone provides a globally standardized scientific identity, enhancing international clarity and regulatory positioning, and supports the advancement of olastrocel across large unmet-need markets. The therapy targets...
2025-12-02 14:15
The latest update is out from Creative Medical Technology Holdings ( ($CELZ) )....
2025-11-12 19:47
Creative Medical Technology Holdings Announces Agreements for Exercise of Warra...
2025-10-29 21:00